Oral iron chelation with deferiprone (Q34418689)

2 August 2017

1 reference

title

Oral iron chelation with deferiprone (English)

1 reference

2 August 2017

O Diav-Citrin

1 reference

2 August 2017

G Koren

series ordinal

1 reference

2 August 2017

publication date

1 February 1997

1 reference

Pediatric Clinics of North America

2 August 2017

published in

1 reference

2 August 2017

1 reference

2 August 2017

1 reference

2 August 2017

page(s)

235-247

1 reference

Oral iron chelation: a review with special emphasis on Indian work on deferiprone (L1).

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970471-5

Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970471-5

Oral iron chelation with L1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970471-5

Results of long‐term deferiprone (L1) therapy: a report by the International Study Group on Oral Iron Chelators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970471-5

Oral iron-chelating therapy: the L1 experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970471-5

Pharmacokinetics of the oral iron chelator deferiprone (L1) in patients with iron overload.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970471-5

Serum non-transferrin-bound iron in beta-thalassaemia major patients treated with desferrioxamine and L1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970471-5

Agranulocytosis in a patient with thalassaemia major during treatment with the oral iron chelator, 1,2-dimethyl-3-hydroxypyrid-4-one

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970471-5

The effect of deferiprone (L1) and desferrioxamine on myelopoiesis using a liquid culture system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970471-5

Deferiprone-associated myelotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970471-5

Zinc concentration in patients with iron overload receiving oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one or desferrioxamine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970471-5

Long-term Chelation Therapy in Thalassaemia Major: Effect on Liver Iron Concentration, Liver Histology, and Clinical Progress

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970471-5

Long-term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1). II. Clinical observations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970471-5

Cardioprotective effect of desferrioxamine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970471-5

Arthropathy in thalassaemia patients receiving deferiprone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970471-5

Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970471-5

Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970471-5

Differential toxicity of alpha-keto hydroxypyridine iron chelators and desferrioxamine to human haemopoietic precursors in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970471-5

Role of deferoxamine in tumor therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970471-5

LATE CARDIAC COMPLICATIONS OF CHRONIC, SEVERE, REFRACTORY ANEMIA WITH HEMOCHROMATOSIS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970471-5

Efficacy of deferiprone in the treatment of acute iron intoxication in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970471-5

Low-molecular-weight iron complexes and oxygen radical reactions in idiopathic haemochromatosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970471-5

Oxygen free radicals and iron in relation to biology and medicine: some problems and concepts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970471-5

Prevention of anthracycline cardiotoxicity by iron chelation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970471-5

Iron chelators induce apoptosis in proliferating cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970471-5

Agranulocytosis and thrombocytopenia in patient with Blackfan-Diamond anaemia during oral chelator trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970471-5

THE BIOCHEMISTRY OF DESFERRIOXAMINE AND ITS RELATION TO IRON METABOLISM

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970471-5

Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970471-5

1,2-Dimethyl-3-hydroxypyrid-4-one, an orally active chelator for treatment of iron overload

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970471-5

Long-term trial with the oral iron chelator 1, 2-dimethyl-3-hydroxypyrid-4-one (L1). I. Iron chelation and metabolic studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970471-5

Pharmacokinetic studies in humans with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970471-5

1992 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970471-5

Clinical studies of iron chelators in malaria.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970471-5

Acute iron poisoning. Rescue with macromolecular chelators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970471-5

Use of iron chelators in preventing hydroxyl radical damage: adult respiratory distress syndrome as an experimental model for the pathophysiology and treatment of oxygen-radical-mediated tissue damage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970471-5

Relationship between the pharmacokinetics and iron excretion pharmacodynamics of the new oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in patients with thalassemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970471-5

Treatment of acute iron ingestion with deferoxamine in 20 children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970471-5

The metabolism of desferrioxamine B and ferrioxamine B

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970471-5

Iron-chelation therapy with oral deferiprone in patients with thalassemia major

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970471-5

Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970471-5

Growth Failure and Bony Changes Induced by Deferoxamine

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970471-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970471-5

inferred from DOI database lookup

7 January 2021

based on heuristic

Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970471-5

Survival in medically treated patients with homozygous beta-thalassemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970471-5

Distribution and renal excretion of desferrioxamine and ferrioxamine in the dog and in the rat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970471-5

Evaluation of new iron chelators for clinical use.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970471-5

The development of iron chelating drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970471-5

Continuous subcutaenous administration of deferoxamine in patients with iron overload

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970471-5

Management of acute iron poisoning

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970471-5

Iron removal therapy in porphyria cutanea tarda: phlebotomy versus slow subcutaneous desferrioxamine infusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970471-5

L1 (1,2-dimethyl-3-hydroxypyrid-4-one) for oral iron chelation in patients with beta-thalassaemia major

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970471-5

Deferoxamine in the treatment of acute iron poisoning. Clinical experiences with 172 children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970471-5

THE TREATMENT OF HAEMOCHROMATOSIS WITH DESFERRIOXAMINE

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970471-5

Bark, weeds, and iron chelators--drugs for malaria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970471-5

10.1016/S0031-3955(05)70471-5

7 January 2021

Identifiers

DOI

1 reference

2 August 2017

1 reference